Home › Companies › EXEL

EXELIXIS, INC.

EXEL Lead: NDA Submitted 4 Biotech Distilled articles ↓

Most recent annual filing: 2026-02-15

Pipeline (2 active programs)

zanzalintinib

Target: TYRO3, AXL, MER, MET, VEGFR

Colorectal Cancer NDA Submitted oral Merck
Recurrent Meningioma Phase 2 Merck

Biotech Distilled coverage (4)

2026-05-06 UPDATE: Exelixis (EXEL) - Q1 prints another cash-gusher quarter and the Board just stacked another $750M on the buyback pile. 🔒 Paid
2026-02-14 UPDATE: Exelixis (EXEL) - The Receipts Are In 🔒 Paid
2026-02-07 UPDATE: Exelixis (EXEL) - The Clock Starts Now 🔒 Paid
2026-01-30 Exelixis Inc.(EXEL): Scientific Deep Dive for Zanza and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.